Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?

被引：11
|
作者：
Chiang, Kelly [1 ]
Davies, Clare C. [1 ]
机构：
[1] Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Birmingham, W Midlands, England
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2018年 / 5卷 / 03期
基金：
英国医学研究理事会;
关键词：
PRMT5; breast cancer stem cells; epigenetics; arginine methylation; FOXP1;
D O I：
10.1080/23723556.2018.1441628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arginine methyitransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Role of PRMT1 and PRMT5 in Breast Cancer
    Martinez, Sebastien
    Sentis, Stephanie
    Poulard, Coralie
    Tredan, Olivier
    Le Romancer, Muriel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [2] PRMT5: a putative oncogene and therapeutic target in prostate cancer
    Beketova, Elena
    Owens, Jake L.
    Asberry, Andrew M.
    Hu, Chang-Deng
    CANCER GENE THERAPY, 2022, 29 (3-4) : 264 - 276
  • [3] PRMT5 regulates the chemoresistnace of ovarian cancer cells
    Do, Yen Thi
    Kim, Jin Young
    Lee, Seungmee
    Vo, Tam Thuy Lu
    Pham, Thi Tuyet Mai
    Ha, Eunyoung
    Cho, Chi-Heum
    Shin, So-Jin
    Seo, Ji Hae
    CANCER RESEARCH, 2023, 83 (07)
  • [4] PRMT5: a putative oncogene and therapeutic target in prostate cancer
    Elena Beketova
    Jake L. Owens
    Andrew M. Asberry
    Chang-Deng Hu
    Cancer Gene Therapy, 2022, 29 : 264 - 276
  • [5] PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells
    Bajbouj, Khuloud
    Ramakrishnan, Rakhee K.
    Saber-Ayad, Maha
    Omar, Hany A.
    Saheb Sharif-Askari, Narjes
    Shafarin, Jasmin
    Elmoselhi, Adel B.
    Ihmaid, Ahmed
    AlHaj Ali, Suhib
    Alalool, Abdulla
    Abdullah, Reem
    Hamid, Qutayba
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [6] A new move for PRMT5
    Joanna E. Huddleston
    Nature Reviews Molecular Cell Biology, 2011, 12 : 76 - 76
  • [7] Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer
    Brobbey, Charles
    Yin, Shasha
    Liu, Liu
    Ball, Lauren E.
    Howe, Philip H.
    Delaney, Joe R.
    Gan, Wenjian
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer
    Charles Brobbey
    Shasha Yin
    Liu Liu
    Lauren E. Ball
    Philip H. Howe
    Joe R. Delaney
    Wenjian Gan
    Scientific Reports, 13
  • [9] Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
    Elurbide, Jasmin
    Colyn, Leticia
    Latasa, Maria U.
    Uriarte, Iker
    Mariani, Stefano
    Lopez-Pascual, Amaya
    Valbuena, Emiliana
    Castello-Uribe, Borja
    Arnes-Benito, Robert
    Adan-Villaescusa, Elena
    Martinez-Perez, Luz A.
    Azkargorta, Mikel
    Elortza, Felix
    Wu, Hanghang
    Krawczyk, Marcin
    Schneider, Kai Markus
    Sangro, Bruno
    Aldrighetti, Luca
    Ratti, Francesca
    Gardini, Andrea Casadei
    Marin, Jose J. G.
    Amat, Irene
    Urman, Jesus M.
    Arechederra, Maria
    Luz Martinez-Chantar, Maria
    Trautwein, Christian
    Huch, Meritxell
    Javier Cubero, Francisco
    Berasain, Carmen
    Fernandez-Barrena, Maite G.
    Avila, Matias A.
    GUT, 2025, 74 (01) : 116 - 127
  • [10] PRMT5 is a therapeutic target in choroidal neovascularization
    Muniyandi, Anbukkarasi
    Martin, Matthew
    Sishtla, Kamakshi
    Motolani, Aishat
    Sun, Mengyao
    Jensen, Nathan R.
    Qi, Xiaoping
    Boulton, Michael E.
    Prabhu, Lakshmi
    Lu, Tao
    Corson, Timothy W.
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345